Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ACB
ACB logo

ACB Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
3.766
Open
3.650
VWAP
3.69
Vol
777.44K
Mkt Cap
207.56M
Low
3.650
Amount
2.87M
EV/EBITDA(TTM)
--
Total Shares
56.71M
EV
305.86M
EV/OCF(TTM)
--
P/S(TTM)
0.75
Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company’s segments include Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, IndiMed and CraftPlant. The Company also holds a 50.1% controlling interest in Bevo Farms Ltd., a supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.
Show More

Events Timeline

(ET)
2026-03-19
11:20:00
Representative Proposes Bill to Protect Legal Cannabis Businesses
select
link
2026-03-09 (ET)
2026-03-09
08:50:00
Significant Increases in Indicative Borrow Rates for Liquid Options
select
2026-03-05 (ET)
2026-03-05
08:50:00
Klarna Group Borrow Rate Increases to 31.14%
select
2026-02-27 (ET)
2026-02-27
08:50:00
Latest Data Shows Gemini Space Station Borrow Rate Increases to 40.17%
select
2026-02-25 (ET)
2026-02-25
08:50:00
Largest Indicative Borrow Rate Increases Among Liquid Option Names
select
2026-02-19 (ET)
2026-02-19
08:50:00
Beyond Meat Borrow Rate Increases to 52.79%
select
2026-02-18 (ET)
2026-02-18
08:50:00
Innoviz Borrow Rate Increases to 3.84%
select
2026-02-12 (ET)
2026-02-12
08:50:00
Latest Data Shows Euro ETF Borrow Rate Rises to 8.63%
select
2026-02-11 (ET)
2026-02-11
07:20:00
Aurora Cannabis Expands Medical Portfolio in Australia and New Zealand
select

News

seekingalpha
8.5
04-15seekingalpha
Aurora Cannabis Acquires Safari Flower Company for C$26.5M
  • Acquisition Overview: Aurora Cannabis has acquired Safari Flower Company for approximately C$26.5 million, including up to C$2 million in contingent cash payments, indicating a proactive strategy in market consolidation.
  • Equity and Cash Payment: Upon closing, Aurora issued 2,417,180 common shares to the selling shareholder and paid C$15 million in cash, reflecting the company's flexibility and strategic foresight in capital operations.
  • Capacity Enhancement: The 59,000-square-foot EU GMP-certified indoor cultivation and manufacturing facility in Ontario will provide Aurora with incremental capacity to meet supply demands in key international markets such as Germany, Australia, Poland, and the UK.
  • Future Financial Outlook: This transaction is expected to deliver positive adjusted EBITDA contributions in fiscal year 2027, with further benefits anticipated in fiscal year 2028 and beyond, thereby enhancing the company's competitive position in the market.
PRnewswire
8.5
04-15PRnewswire
Aurora Cannabis Acquires Safari Flower Company for $26.5 Million
  • Acquisition Overview: Aurora Cannabis has acquired Safari Flower Company for $26.5 million through a wholly-owned subsidiary, which includes a $2 million cash payment contingent on certain conditions, demonstrating Aurora's commitment to expanding in the international medical cannabis market.
  • Market Expansion Strategy: This acquisition will enhance Aurora's EU GMP-certified production capacity, expected to increase the supply of high-quality cannabis flower, thereby solidifying its leadership in high-margin and highly regulated markets.
  • Financial Impact Expectations: Aurora anticipates that the transaction will yield synergies, boosting revenue and positive cash flow while enhancing Adjusted EBITDA, reflecting the company's confidence in its future financial performance.
  • Global Business Strategy: Aurora aims to optimize its global supply chain through this acquisition, increasing its international market share while providing superior quality products to patients worldwide, embodying its strategic vision of 'Opening the World to Cannabis.'
Newsfilter
8.5
04-15Newsfilter
Aurora Acquires Safari Flower Company for $26.5 Million
  • Acquisition Overview: Aurora Cannabis has acquired Safari Flower Company for $26.5 million, which includes a $2 million cash payment, enhancing Aurora's competitive position in the international medical cannabis market.
  • Market Expansion Strategy: This acquisition will enable Aurora to supply more EU GMP-compliant high-quality cannabis flower to key international markets such as Germany, Australia, Poland, and the UK, further solidifying its market leadership.
  • Financial Expectations: The transaction is expected to deliver positive Adjusted EBITDA contributions in fiscal year 2027, with incremental benefits in fiscal year 2028 and beyond, indicating Aurora's confidence in future financial performance.
  • Operational Efficiency Improvement: Aurora plans to leverage its plant science and operational expertise to enhance cultivation yields and commercial execution, thereby achieving higher operational efficiency in high-margin international markets.
PRnewswire
6.5
03-30PRnewswire
Aurora Named on Women Lead Here List for Second Year
  • Recognition of Leadership: Aurora Cannabis has been named on The Globe and Mail's 2026 Women Lead Here list for the second consecutive year, highlighting the company's ongoing commitment to gender diversity at the executive level, with 50% female executives enhancing its image and ability to attract female talent.
  • Cultural Development: Lori Schick, Executive VP of Human Resources at Aurora, stated that the company fosters a culture of respect, trust, and accountability, enabling female leaders to thrive and drive business forward, thereby improving overall performance and market competitiveness.
  • Industry Impact: The benchmark evaluates executive teams at Canada's largest publicly traded companies using a data-driven methodology that emphasizes sustainable representation, with Aurora standing out among 85 companies, showcasing its leadership position and commitment to diversity in the industry.
  • Strategic Direction: Aurora remains focused on creating an environment that encourages collaboration and diverse perspectives, which not only enhances service quality for patients and communities but also lays a solid foundation for the company's future growth.
Newsfilter
6.5
03-30Newsfilter
Aurora Cannabis Recognized on Women Lead Here List for Second Year
  • Diversity Recognition: Aurora Cannabis has been named on The Globe and Mail's 2026 Women Lead Here list for the second consecutive year, reflecting the company's ongoing commitment to gender diversity at the executive level, with a 50% female leadership ratio that enhances its image and ability to attract female talent.
  • Cultural Development: Lori Schick, Executive Vice President of Human Resources, emphasizes that Aurora fosters a culture grounded in respect, trust, and accountability, enabling female leaders to thrive and drive the company forward, which boosts employee satisfaction and teamwork.
  • Industry Influence: The benchmark evaluates executive teams of Canada's largest publicly traded companies using a data-driven methodology that prioritizes measurable progress and sustained representation, with Aurora's inclusion not only enhancing its reputation in the industry but also setting a standard for others.
  • Global Market Expansion: As a global leader in medical cannabis, Aurora is dedicated to improving patient lives through scientific expertise and high-quality products, continuously expanding its presence in Canada, Europe, Australia, and New Zealand, thereby solidifying its leadership position in the medical cannabis sector.
Fool
5.0
02-26Fool
Aurora Cannabis Faces Significant Challenges Ahead
  • Poor Market Performance: Aurora Cannabis has lost 96% of its stock value since 2021, indicating the company's struggle to establish itself in a highly competitive market; despite cannabis being legalized in Canada since 2018, Aurora has failed to achieve significant success, highlighting deficiencies in its market strategy.
  • Regulatory Change Opportunities: President Trump’s executive order reclassifying cannabis to Schedule III offers research and banking advantages, yet Aurora's negligible presence in the U.S. market limits its potential gains from these changes, constraining growth opportunities.
  • Acquisition Challenges: The acquisition of Reliva, focused on CBD products, in 2020 was undermined by significant challenges in the CBD market, leading to the shutdown of operations in 2023, which underscores the difficulties and risks Aurora faces in expanding into new markets.
  • Bleak Future Outlook: While a potential cannabis market revival exists, Aurora Cannabis's weak revenue growth and consistent net losses present substantial challenges for re-entering the U.S. market, prompting investors to carefully assess the company's future performance amidst these uncertainties.
Wall Street analysts forecast ACB stock price to rise
3 Analyst Rating
Wall Street analysts forecast ACB stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
6.28
Averages
6.77
High
7.39
Current: 0.000
sliders
Low
6.28
Averages
6.77
High
7.39
Canaccord
Buy
downgrade
$10 -> $9
AI Analysis
2026-02-05
Reason
Canaccord
Price Target
$10 -> $9
AI Analysis
2026-02-05
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Aurora Cannabis to C$9 from C$10 and keeps a Buy rating on the shares.
Canaccord
Buy
initiated
$10
2026-01-27
Reason
Canaccord
Price Target
$10
2026-01-27
initiated
Buy
Reason
Canaccord initiated coverage of Aurora Cannabis with a Buy rating and C$10 price target. The medical-first operator is "the leading medical player" in Canada and "a foremost player" in the key international markets of Germany, Poland, Australia, and the UK, the analyst tells investors in a note starting coverage of the the Canadian cannabis group. A domestic pivot supported an expansion into the high-margin international markets, where gross margins are roughly 2.5-times higher, on average, than in Aurora's medically focused Canadian business, the analyst noted.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ACB
Unlock Now

Valuation Metrics

The current forward P/E ratio for Aurora Cannabis Inc (ACB.O) is 19.16, compared to its 5-year average forward P/E of -54.04. For a more detailed relative valuation and DCF analysis to assess Aurora Cannabis Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-54.04
Current PE
19.16
Overvalued PE
298.92
Undervalued PE
-406.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.76
Current EV/EBITDA
7.93
Overvalued EV/EBITDA
39.36
Undervalued EV/EBITDA
-48.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.45
Current PS
0.64
Overvalued PS
4.81
Undervalued PS
0.09

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

Should I Buy cannabis stocks?
Intellectia · 9 candidates
Market Cap: >= 50.00MThemes: The Cannabis IndustryList Exchange: XNYS, XNASMonthly Average Dollar Volume: >= 100,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
4.06B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.29B
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
CGC logo
CGC
Canopy Growth Corp
440.50M
SNDL logo
SNDL
SNDL Inc
386.25M
what cannabis stocks would you buy?
Intellectia · 4 candidates
Market Cap: >= 200.00MPrice: >= $1.00Themes: The Cannabis IndustryQuarter Revenue Yoy Growth: >= 0.0%Monthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
SNDL logo
SNDL
SNDL Inc
386.25M
ACB logo
ACB
Aurora Cannabis Inc
204.15M
cannabis
Intellectia · 8 candidates
Market Cap: >= 200.00MPrice: >= $1.00Themes: The Cannabis IndustryIs Optionable: TrueMonthly Average Dollar Volume: >= 200,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
4.06B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.29B
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
CGC logo
CGC
Canopy Growth Corp
440.50M
SNDL logo
SNDL
SNDL Inc
386.25M
marijuana stocks
Intellectia · 8 candidates
Market Cap: >= 200.00MRegion: US, CanadaPrice: >= $1.00Themes: The Cannabis IndustryList Exchange: XNYS, XNAS, XASEIs Optionable: TrueMonthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
3.70B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.41B
TLRY logo
TLRY
Tilray Brands Inc
1.01B
CRON logo
CRON
Cronos Group Inc
999.35M
CGC logo
CGC
Canopy Growth Corp
460.70M
SNDL logo
SNDL
SNDL Inc
406.85M
Top cannabis stocks to buy
Intellectia · 9 candidates
Market Cap: >= 50.00MRevenue Ttm: >= 10.00MThemes: The Cannabis Industry
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
3.70B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.41B
TLRY logo
TLRY
Tilray Brands Inc
1.01B
CRON logo
CRON
Cronos Group Inc
999.35M
CGC logo
CGC
Canopy Growth Corp
460.70M
SNDL logo
SNDL
SNDL Inc
406.85M

Whales Holding ACB

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Aurora Cannabis Inc (ACB) stock price today?

The current price of ACB is 3.66 USD — it has increased 1.39

What is Aurora Cannabis Inc (ACB)'s business?

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company’s segments include Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, IndiMed and CraftPlant. The Company also holds a 50.1% controlling interest in Bevo Farms Ltd., a supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.

What is the price predicton of ACB Stock?

Wall Street analysts forecast ACB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACB is6.77 USD with a low forecast of 6.28 USD and a high forecast of 7.39 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Aurora Cannabis Inc (ACB)'s revenue for the last quarter?

Aurora Cannabis Inc revenue for the last quarter amounts to 94.19M USD, increased 6.79

What is Aurora Cannabis Inc (ACB)'s earnings per share (EPS) for the last quarter?

Aurora Cannabis Inc. EPS for the last quarter amounts to 0.03 USD, decreased -94.23

How many employees does Aurora Cannabis Inc (ACB). have?

Aurora Cannabis Inc (ACB) has 1101 emplpoyees as of April 19 2026.

What is Aurora Cannabis Inc (ACB) market cap?

Today ACB has the market capitalization of 207.56M USD.